非酒精性脂肪性肝病及其与心血管疾病和其他肝外疾病的关系
综述阐述非酒精性脂肪性肝病(NAFLD)与心血管疾病、慢性肾病和2型糖尿病的独立关联,风险随NAFLD严重程度增加,非酒精性脂肪性肝炎(NASH)患者风险高于单纯性脂肪变。NAFLD改善或缓解与2型糖尿病发病率降低和肾功能改善相关,建议将心血管风险因素管理、2型糖尿病和慢性肾病筛查纳入NAFLD常规管理。
要点
- NAFLD与心血管疾病、慢性肾病和2型糖尿病独立相关。
- NASH患者发生心血管疾病、慢性肾病和2型糖尿病的风险高于单纯性脂肪变患者。
- NAFLD改善或缓解与2型糖尿病发病率降低和肾功能改善相关。
核心结论
- NAFLD与心血管疾病、慢性肾病和2型糖尿病独立相关,风险随NAFLD严重程度增加,NASH患者风险高于单纯性脂肪变。
- NAFLD改善或缓解与2型糖尿病发病率降低和肾功能改善相关,支持以肝脏为靶点的治疗可能降低肝外并发症风险。
- 临床医生应将心血管风险因素管理、2型糖尿病和慢性肾病筛查纳入NAFLD患者的常规管理。
研究设计与样本
- 综述,阐述NAFLD与心血管疾病及其他肝外疾病的关联。
主要发现
- NAFLD与现患和 incident 心血管疾病、慢性肾病和2型糖尿病独立相关。
- NASH患者发生心血管疾病、慢性肾病和2型糖尿病的风险高于单纯性脂肪变患者。
- 其他风险修饰因素可能包括遗传变异(如PNPLA3和TM6SF2多态性)、内脏脂肪堆积、膳食摄入和肠道微生物组。
- 新出现的数据提示NAFLD可能是结肠肿瘤和骨密度降低(尤其在男性中)的风险因素。
- NAFLD改善或缓解与2型糖尿病发病率降低和肾功能改善相关。
临床怎么用
- 临床医生应将心血管风险因素管理、2型糖尿病筛查和慢性肾病筛查作为NAFLD患者常规管理的一部分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Key physiological functions of the liver, including glucose and lipid metabolism, become disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated with a systemic inflammatory 'milieu' initiated in part by liver-secreted cytokines and molecules. Consequently, the pathophysiological effects of NAFLD extend beyond the liver with a large body of clinical evidence demonstrating NAFLD to be independently associated with both prevalent and incident cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). The magnitude of risk of developing these extrahepatic diseases parallels the underlying severity of NAFLD, such that patients with non-alcoholic steatohepatitis (NASH) appear to be at greater risk of incident CVD, CKD and T2DM than those with simple steatosis. Other modifiers of risk may include genetic variants (eg, patatin-like phospholipase domain-containing 3 and trans-membrane 6 superfamily member 2 polymorphisms), visceral adipose tissue accumulation, dietary intake and the gut microbiome. Emerging data also suggest that NAFLD may be a risk factor for colonic neoplasia and reduced bone mineral density, especially among men. Importantly, improvement/resolution of NAFLD is associated with a reduced incidence of T2DM and improved kidney function, adding weight to causality and suggesting liver focused treatments may reduce risk of extrahepatic complications. Awareness of these associations is important for the clinicians such that CVD risk factor management, screening for T2DM and CKD are part of the routine management of patients with NAFLD.
引用
- Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017. PMID: 28314735. doi:10.1136/gutjnl-2017-313884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。